



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

March 2015





HIV/AIDS Drug Treatment Program

Monthly Report

© 2015 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.682.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

March 2015

N = 6846



Health Authority	Male	Female	All
FRASER	1262	383	1645
INTERIOR	333	96	429
NORTHERN	126	81	207
VANCOUVER COASTAL	3304	434	3738
VANCOUVER ISLAND	620	145	765
	5645	1139	6784
		Unknown/not stated:	62
		Total:	6846

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2010 - March 2015)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2010 - March 2015)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (March 2010 - March 2015)






1.5 BC-CfE Enrollment: New Antiretroviral Participants
(March 2010 - March 2015)






1.6 Percent Distribution of Active Participants by CD4 Count (March 2010 - March 2015)






1.7 Percent Distribution of Inactive Participants by CD4 Count (March 2010 - March 2015)






1.8 Active and Inactive Participants (March 2010 - March 2015)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (March 2010 - March 2015)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (March 2010 - March 2015)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(March 2010 - March 2015)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (March 2010 - March 2015)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(March 2010 - March 2015)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (March 2010 - March 2015)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(March 2010 - March 2015)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (March 2010 - March 2015)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(March 2010 - March 2015)






1.18 Baseline CD4 for Antiretroviral First Starts (March 2010 - March 2015)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(March 2010 - March 2015)**






1.20 Cumulative Resistance Testing Results by Resistance Category (March 2010 - March 2015)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (March 2010 - March 2015)





2.1 Duration of ARV treatment in the Province of BC, 1987-2015 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	660	5	<40	4
1988	23	8	0	8	8	490	8	<40	4
1989	22	57	2	59	54	540	58	<40	4
1990	21	64	1	65	60	510	64	<40	4
1991	21	38	3	41	35	590	41	<40	4
1992	21	68	7	75	56	570	75	<40	4
1993	20	147	14	161	146	565	158	<40	4
1994	19	94	12	106	84	550	104	<40	4
1995	18	126	26	152	126	575	146	<40	4
1996	16	383	63	446	375	570	427	<40	4
1997	14	319	39	358	324	600	353	<40	3
1998	14	224	45	269	222	570	253	<40	3
1999	13	189	43	232	196	560	224	<40	3
2000	14	145	39	184	153	580	177	<40	3
2001	13	136	39	175	147	580	169	<40	3
2002	12	140	34	174	141	530	163	<40	3
2003	11	181	33	214	182	575	207	<40	3
2004	10	178	46	224	193	560	211	<40	3
2005	10	213	56	269	228	620	261	<40	4
2006	9	227	50	277	228	540	265	<40	4
2007	8	290	56	346	283	580	327	<40	3
2008	7	324	78	402	335	620	384	<40	3
2009	6	353	76	429	364	610	412	<40	3
2010	5	317	75	392	329	610	372	<40	3
2011	4	381	82	463	401	620	452	<40	3
2012	3	324	70	394	338	620	383	<40	3
2013	2	303	80	383	304	630	365	<40	3
2014	1	338	63	401	355	600	393	<40	4
2015	0	108	17	125	118	500	119	415	3
Total:		5680	1149	6829					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	785	2429	<40	2151	560
FEB-2014	6570	785	1895	<40	1656	550
MAR-2014	6598	788	2156	<40	1927	550
APR-2014	6611	790	2126	<40	1871	560
MAY-2014	6677	769	2119	<40	1887	560
JUN-2014	6644	784	1994	<40	1766	550
JUL-2014	6682	780	2179	<40	1930	550
AUG-2014	6703	775	2026	<40	1803	570
SEP-2014	6730	770	2284	<40	2001	550
OCT-2014	6761	764	2250	<40	1954	570
NOV-2014	6759	761	1920	<40	1700	580
DEC-2014	6772	766	1895	<40	1677	580
JAN-2015	6747	762	2428	<40	2080	580
FEB-2015	6807	753	1980	<40	1668	570
MAR-2015	6846	748	2174	<40	1797	570

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1418	2266	100	6683	76	285
FEB-2014	1439	2213	73	496	67	490
MAR-2014	1441	2179	115	3890	98	340
APR-2014	1451	2159	112	128	90	400
MAY-2014	1422	2331	90	617	76	350
JUN-2014	1475	2074	96	423	82	380
JUL-2014	1467	2119	95	982	76	355
AUG-2014	1459	2183	87	208	72	365
SEP-2014	1459	2191	104	949	90	395
OCT-2014	1446	2278	84	257	62	395
NOV-2014	1459	2246	74	3945	64	400
DEC-2014	1479	2218	93	557	71	340
JAN-2015	1516	2087	105	1364	82	290
FEB-2015	1490	2201	98	74	81	390
MAR-2015	1471	2314	102	66	86	395

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1418	2	30	144	136	35	11501
FEB-2014	6548	1439	9	40	139	159	9	11545
MAR-2014	6573	1441	9	36	151	146	25	11589
APR-2014	6587	1451	5	27	159	161	14	11625
MAY-2014	6646	1422	14	38	191	152	59	11675
JUN-2014	6618	1475	7	24	142	183	-28	11713
JUL-2014	6659	1467	8	34	176	159	41	11757
AUG-2014	6683	1459	6	18	165	149	24	11789
SEP-2014	6713	1459	2	25	168	159	30	11828
OCT-2014	6739	1446	7	21	160	146	26	11855
NOV-2014	6733	1459	12	19	135	144	-6	11879
DEC-2014	6748	1479	7	39	135	147	15	11928
JAN-2015	6717	1516	12	23	148	184	-31	11963
FEB-2015	6780	1490	7	37	190	156	63	12016
MAR-2015	6829	1471	4	30	171	147	49	12057

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	6557	0.72%	91.89%	6.31%	1.08%	100.00%
FEB-2014	50	6034	418	68	6570	0.76%	91.84%	6.36%	1.04%	100.00%
MAR-2014	50	6054	424	70	6598	0.76%	91.76%	6.43%	1.06%	100.00%
APR-2014	46	6067	422	76	6611	0.70%	91.77%	6.38%	1.15%	100.00%
MAY-2014	47	6138	418	74	6677	0.70%	91.93%	6.26%	1.11%	100.00%
JUN-2014	49	6108	416	71	6644	0.74%	91.93%	6.26%	1.07%	100.00%
JUL-2014	46	6148	415	73	6682	0.69%	92.01%	6.21%	1.09%	100.00%
AUG-2014	46	6171	414	72	6703	0.69%	92.06%	6.18%	1.07%	100.00%
SEP-2014	50	6184	425	71	6730	0.74%	91.89%	6.32%	1.05%	100.00%
OCT-2014	44	6210	434	73	6761	0.65%	91.85%	6.42%	1.08%	100.00%
NOV-2014	47	6218	424	70	6759	0.70%	92.00%	6.27%	1.04%	100.00%
DEC-2014	43	6234	421	74	6772	0.63%	92.06%	6.22%	1.09%	100.00%
JAN-2015	43	6190	440	74	6747	0.64%	91.74%	6.52%	1.10%	100.00%
FEB-2015	42	6238	453	74	6807	0.62%	91.64%	6.65%	1.09%	100.00%
MAR-2015	43	6300	437	66	6846	0.63%	92.02%	6.38%	0.96%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2382 37%	7 17%	1995 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3864 61%	36 86%	4271 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3881 61%	37 84%	4287 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2431 38%	9 24%	2063 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	29 76%	3905 61%	29 76%	4293 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3918 60%	32 73%	4298 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3913 60%	24 77%	4287 66%
SEP-2014	15 38%	2517 39%	12 31%	2146 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3905 60%	24 62%	4285 66%
OCT-2014	10 37%	2546 39%	9 33%	2173 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3907 60%	17 63%	4288 65%
NOV-2014	6 25%	2548 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3897 59%	19 79%	4270 65%
DEC-2014	13 27%	2576 39%	9 18%	2205 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3877 59%	37 76%	4249 65%
JAN-2015	10 29%	2585 40%	10 29%	2222 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3854 59%	25 71%	4218 64%
FEB-2015	10 19%	2596 39%	10 19%	2231 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	43 81%	3900 59%	43 81%	4262 65%
MAR-2015	11 27%	2612 39%	11 27%	2255 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 73%	3924 59%	30 73%	4280 64%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	740 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	762 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2139 62%	6 46%	868 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2133 62%	5 50%	889 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2107 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2076 61%	12 55%	922 27%	3 14%	385 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2032 60%	6 50%	933 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	9 33%	2036 60%	18 67%	964 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2047 60%	8 47%	974 29%	0 0%	376 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 50%	1280 46%	1 13%	303 11%	1 13%	926 34%	2 25%	258 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	257 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1232 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1208 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1191 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	901 34%	2 25%	254 10%
FEB-2015	4 50%	1172 45%	0 0%	306 12%	0 0%	893 34%	4 50%	251 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	890 34%	1 13%	255 10%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	77 6%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	253 17%	0 0%	75 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	268 18%	0 0%	75 5%	2 18%	919 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	281 18%	0 0%	74 5%	4 27%	919 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	309 19%	0 0%	71 4%	2 13%	906 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 29%	6 35%	336 19%	0 0%	72 4%	0 0%	888 51%	0 0%	1 0%
JAN-2015	13 72%	541 30%	4 22%	350 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	15 63%	578 31%	7 29%	359 19%	0 0%	74 4%	2 8%	882 48%	0 0%	1 0%
MAR-2015	10 53%	602 32%	5 26%	370 20%	0 0%	69 4%	4 21%	870 47%	0 0%	2 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.66	2246	33.80	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.31	2235	33.45	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.30	890	13.28	186	2.77	72	1.07	858	12.80
SEP-2014	2437	36.21	2221	33.00	945	14.04	187	2.78	71	1.05	869	12.91
OCT-2014	2420	35.79	2191	32.41	1008	14.91	192	2.84	73	1.08	877	12.97
NOV-2014	2422	35.83	2160	31.96	1056	15.62	184	2.72	70	1.04	867	12.83
DEC-2014	2400	35.44	2146	31.69	1104	16.30	185	2.73	74	1.09	863	12.74
JAN-2015	2354	34.89	2125	31.50	1138	16.87	179	2.65	74	1.10	877	13.00
FEB-2015	2373	34.86	2115	31.07	1180	17.34	178	2.61	74	1.09	887	13.03
MAR-2015	2406	35.14	2113	30.86	1206	17.62	185	2.70	66	0.96	870	12.71

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	24	3	1	6	6	7	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	19	5	1	0	4	8	475
DEC-2014	39	3	5	7	11	13	401
JAN-2015	23	2	2	8	3	8	320
FEB-2015	37	3	3	8	5	16	457
MAR-2015	30	2	5	5	9	7	393

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10030	2580
FEB-2014	10053	2574
MAR-2014	10066	2560
APR-2014	10096	2563
MAY-2014	10120	2557
JUN-2014	10155	2567
JUL-2014	10167	2555
AUG-2014	10216	2589
SEP-2014	10258	2599
OCT-2014	10281	2608
NOV-2014	10312	2630
DEC-2014	10353	2634
JAN-2015	10396	2664
FEB-2015	10442	2670
MAR-2015	10487	2681

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
March 2015

N = 6846

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2015

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	11	13	8
	50+	19	29	13
	Total HSDA:	30	42	21
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	3	3	1
	35-49	19	24	13
	50+	44	58	35
	Total HSDA:	67	86	50
OKANAGAN	0-19	3	3	1
	20-34	20	21	16
	35-49	92	108	69
	50+	177	259	138
	Total HSDA:	292	391	224
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	16	16	12
	35-49	57	73	46
	50+	89	125	75
	Total HSDA:	168	220	134
Total HA:		557	739	429

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	3
	20-34	39	40	29
	35-49	179	218	136
	50+	329	471	261
Total HA:		557	739	429

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	429	582	333
Female	128	157	96

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	429	52	530	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	6	4
	<5 years	8	7
	Total HSDA:	30	21
KOOTENAY BOUNDARY	10 years or more	32	22
	5 years or more	17	14
	<5 years	18	14
	Total HSDA:	67	50
OKANAGAN	10 years or more	152	107
	5 years or more	75	59
	<5 years	65	58
	Total HSDA:	292	224
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	83	59
	5 years or more	34	31
	<5 years	51	44
	Total HSDA:	168	134
Total HA:		557	429

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	283	198
	5 years or more	132	108
	<5 years	142	123
Total HA:		557	429

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	33	45	12	18
KOOTENAY BOUNDARY	58	105	26	40
OKANAGAN	185	628	69	221
THOMPSON/CARIBOO/SHUSWAP	121	400	43	105
Total:	397	1178	150	384

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	2
KOOTENAY BOUNDARY	12
OKANAGAN	37
THOMPSON/CARIBOO/SHUSWAP	36
Total:	87

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	22	23	16
	35-49	128	141	92
	50+	145	202	117
	Total HSDA:	302	373	230
FRASER NORTH	0-19	21	21	5
	20-34	102	103	86
	35-49	362	415	274
	50+	435	675	360
	Total HSDA:	920	1214	725
FRASER SOUTH	0-19	13	13	5
	20-34	94	95	75
	35-49	358	406	296
	50+	374	562	314
	Unknown	0	1	0
	Total HSDA:	839	1077	690
Total HA:		2061	2664	1645

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	41	41	15
	20-34	218	221	177
	35-49	848	962	662
	50+	954	1439	791
	Unknown	0	1	0
Total HA:		2061	2664	1645

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1555	2043	1262
Female	506	621	383

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1645	49	590	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	132	95
	5 years or more	94	74
	<5 years	76	61
	Total HSDA:	302	230
FRASER NORTH	10 years or more	430	315
	5 years or more	234	186
	<5 years	256	224
	Total HSDA:	920	725
FRASER SOUTH	10 years or more	379	295
	5 years or more	220	187
	<5 years	240	208
	Total HSDA:	839	690
Total HA:		2061	1645

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	941	705
	5 years or more	548	447
	<5 years	572	493
Total HA:		2061	1645

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	122	363	41	73
FRASER NORTH	224	1326	67	267
FRASER SOUTH	197	1138	44	355
Total:	543	2827	152	695

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	178
FRASER NORTH	602
FRASER SOUTH	467
Total:	1247

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	19	19	17
	35-49	86	100	72
	50+	191	309	165
	Total HSDA:	298	430	254
RICHMOND	0-19	8	8	2
	20-34	17	17	14
	35-49	51	54	42
	50+	66	105	54
	Total HSDA:	142	184	112
VANCOUVER	0-19	59	62	8
	20-34	396	405	305
	35-49	1658	1952	1272
	50+	2249	3750	1787
	Total HSDA:	4362	6169	3372
Total HA:	4802	6783	3738	

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	69	72	10
	20-34	432	441	336
	35-49	1795	2106	1386
	50+	2506	4164	2006
Total HA:		4802	6783	3738

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4213	5958	3304
Female	587	823	434

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3738	50	590	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	167	136
	5 years or more	47	43
	<5 years	84	75
	Total HSDA:	298	254
RICHMOND	10 years or more	67	47
	5 years or more	32	24
	<5 years	43	41
	Total HSDA:	142	112
VANCOUVER	10 years or more	2150	1554
	5 years or more	1062	862
	<5 years	1150	956
	Never on ART	0	0
	Total HSDA:	4362	3372
Total HA:	4802	3738	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2384	1737
	5 years or more	1141	929
	<5 years	1277	1072
	Never on ART	0	0
Total HA:		4802	3738

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	137	354	53	86
RICHMOND	42	264	14	93
VANCOUVER	511	9498	203	5147
Total:	690	10116	270	5326

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	5
RICHMOND	2
VANCOUVER	89
Total:	96

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	18	20	15
	35-49	82	97	72
	50+	147	237	117
	Total HSDA:		249	356
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	12	13	6
	35-49	37	42	30
	50+	54	81	45
	Total HSDA:		105	138
SOUTH VANCOUVER ISLAND	0-19	9	9	1
	20-34	43	45	30
	35-49	212	253	161
	50+	363	563	286
	Total HSDA:		627	870
Total HA:		981	1364	765

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	3
	20-34	73	78	51
	35-49	331	392	263
	50+	564	881	448
Total HA:		981	1364	765

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	791	1104	620
Female	190	260	145

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	765	51	450	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	113	87
	5 years or more	65	57
	<5 years	71	61
	Total HSDA:	249	205
NORTH VANCOUVER ISLAND	10 years or more	47	35
	5 years or more	21	17
	<5 years	37	30
	Total HSDA:	105	82
SOUTH VANCOUVER ISLAND	10 years or more	307	213
	5 years or more	153	120
	<5 years	167	145
	Total HSDA:	627	478
Total HA:		981	765

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	467	335
	5 years or more	239	194
	<5 years	275	236
Total HA:		981	765

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	166	509	84	163
NORTH VANCOUVER ISLAND	109	224	47	67
SOUTH VANCOUVER ISLAND	178	1470	48	510
Total:	453	2203	179	740

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	42
NORTH VANCOUVER ISLAND	31
SOUTH VANCOUVER ISLAND	78
Total:	151

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	5	6	4
	35-49	18	21	10
	50+	14	18	10
	Total HSDA:	38	46	24
NORTH WEST	0-19	2	2	0
	20-34	9	13	7
	35-49	23	34	19
	50+	30	43	21
	Total HSDA:	64	92	47
NORTHERN INTERIOR	0-19	1	1	0
	20-34	30	33	26
	35-49	69	85	55
	50+	71	115	55
	Total HSDA:	171	234	136
Total HA:		273	372	207

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	4	4	0
	20-34	44	52	37
	35-49	110	140	84
	50+	115	176	86
Total HA:		273	372	207

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	169	234	126
Female	104	138	81

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	207	46	490	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	12	7
	5 years or more	10	6
	<5 years	16	11
	Total HSDA:	38	24
NORTH WEST	10 years or more	17	9
	5 years or more	22	18
	<5 years	25	20
	Total HSDA:	64	47
NORTHERN INTERIOR	10 years or more	45	28
	5 years or more	48	43
	<5 years	78	65
	Total HSDA:	171	136
Total HA:		273	207

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	74	44
	5 years or more	80	67
	<5 years	119	96
Total HA:		273	207

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries NORTHERN Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	28	54	5	8
NORTH WEST	60	138	19	26
NORTHERN INTERIOR	94	364	24	179
Total:	182	556	48	213

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	17
NORTHERN INTERIOR	23
Total:	47

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	9	6
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	15	28	7
	THOMPSON/CARIBOO/SHUSWAP	21	36	19
	Total HA:	45	79	35
FRASER	FRASER EAST	33	41	28
	FRASER NORTH	64	92	45
	FRASER SOUTH	70	96	54
	Total HA:	167	229	127
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	23	42	20
	RICHMOND	9	14	8
	VANCOUVER	473	744	404
	Total HA:	505	800	432
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	44	69	37
	NORTH VANCOUVER ISLAND	13	22	11
	SOUTH VANCOUVER ISLAND	33	67	28
	Total HA:	90	158	76
NORTHERN	NORTH EAST	10	12	7
	NORTH WEST	29	50	23
	NORTHERN INTERIOR	62	91	56
	Total HA:	101	153	86
Total:		908	1419	756

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	577	915	473
Female	331	504	283

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	756	48	460	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: Persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Combination Therapy: using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

Complera (CPL): the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.





Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (DTG): an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

Efavirenz (Sustiva, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

Emtricitabine (FTC): a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

Famciclovir (Famvir): a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.





Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (MVC, Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: The net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).





Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

Tenofovir (Viread, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Trizivir (TRZ): ViiV Healthcare's trade name for a pill that combines ABACAVIR (ABC), ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

Truvada (TRU): the Gilead trade name for a pill that contains both TENOFOVIR and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

